KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Asset Writedowns and Impairment (2016 - 2025)

Bausch Health Companies' Asset Writedowns and Impairment history spans 12 years, with the latest figure at $7.0 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 69.57% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $8.0 million, down 72.41%, while the annual FY2025 figure was $8.0 million, 72.41% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $7.0 million at Bausch Health Companies, up from $1.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $148.0 million in Q1 2021 and bottomed at $1.0 million in Q3 2022.
  • The 5-year median for Asset Writedowns and Impairment is $8.0 million (2022), against an average of $22.7 million.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 4600.0% in 2021 before it tumbled 94.59% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $21.0 million in 2021, then crashed by 95.24% to $1.0 million in 2022, then soared by 300.0% to $4.0 million in 2023, then surged by 475.0% to $23.0 million in 2024, then plummeted by 69.57% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's Asset Writedowns and Impairment are $7.0 million (Q4 2025), $1.0 million (Q3 2025), and $23.0 million (Q4 2024).